Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".[1][2]
Ifinatamab-DXd is in phase III clinical trials for extensive stage small cell lung carcinoma (EC-SCLC) from 2024 onward.[3] I-DXd progressed directly from Phase I to Phase III, due to exceptional response rates (>65% ORR) in a difficult to treat cancer. I-DXd is also in Phase III trials for metastatic castration resistant prostate cancer from 2025[4]
References
- Len Katsumata, Tsuneo Deguchi, Jun Hasegawa, Michiko Yamato, Yumi Nishiya, Akiko Watanabe, Tomoyo Honda, Megumi Minami. Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization Cancer Research, 4 April 2023^
- M.R. Patel, T. Doi, T. Koyama, G.S. Falchook, C.F. Friedman, S.A. Piha-Paul, M. Gutierrez, M.M. Awad. 690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study Annals of Oncology, October 2023^
- IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer Merck, 1 August 2024, retrieved 29 September 2025^
- IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer Merck, 18 June 2025, retrieved 29 September 2025^